In the last ten years, TNF-α inhibitors have transformed the treatment of axial spondyloarthritis, including ankylosing spondylitis and nonradiographic axial spondyloarthritis, and have brought new attention to this enigmatic autoimmune disease. Today, a second wave of biological therapies is being approved for this indication, and their success will be shaped by the remaining unmet needs within this population. In this report, we examine areas of unmet need in the treatment of axial spondyloarthritis, including current therapies’ lack of demonstrated ability to inhibit radiographic progression and the lack of FDA-approved therapies for axial spondyloarthritis patients without signs of radiographic damage.
- What are the treatment drivers and goals for axial spondyloarthritis?
- What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for axial spondyloarthritis?
- What are the prevailing areas of unmet need and opportunity in axial spondyloarthritis?
- What trade-offs across different clinical attributes and prices are acceptable to U.S. and European rheumatologists for a hypothetical new axial spondyloarthritis drug?
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European rheumatologists fielded in December 2017
Key companies: AbbVie, Amgen, AstraZeneca, Janssen, Novartis, Pfizer
Key drugs: Celebrex, Cosentyx, Enbrel, Humira, Remicade, Vimovo